GR1006552B - Ενδοπροστατικο ελατηριο-δοκιδα-βελονα/εγχυση/ενεσιμη μεθοδος - Google Patents
Ενδοπροστατικο ελατηριο-δοκιδα-βελονα/εγχυση/ενεσιμη μεθοδοςInfo
- Publication number
- GR1006552B GR1006552B GR20080100303A GR20080100303A GR1006552B GR 1006552 B GR1006552 B GR 1006552B GR 20080100303 A GR20080100303 A GR 20080100303A GR 20080100303 A GR20080100303 A GR 20080100303A GR 1006552 B GR1006552 B GR 1006552B
- Authority
- GR
- Greece
- Prior art keywords
- tissues
- rapamycin
- stent
- lymph
- prostate
- Prior art date
Links
- QFJCIRLUMZQUOT-HPLJOQBZSA-N sirolimus Chemical compound C1C[C@@H](O)[C@H](OC)C[C@@H]1C[C@@H](C)[C@H]1OC(=O)[C@@H]2CCCCN2C(=O)C(=O)[C@](O)(O2)[C@H](C)CC[C@H]2C[C@H](OC)/C(C)=C/C=C/C=C/[C@@H](C)C[C@@H](C)C(=O)[C@H](OC)[C@H](O)/C(C)=C/[C@@H](C)C(=O)C1 QFJCIRLUMZQUOT-HPLJOQBZSA-N 0.000 title abstract 4
- 206010060862 Prostate cancer Diseases 0.000 title 1
- 208000000236 Prostatic Neoplasms Diseases 0.000 title 1
- 108010079723 Shiga Toxin Proteins 0.000 title 1
- 206010020718 hyperplasia Diseases 0.000 title 1
- 201000001514 prostate carcinoma Diseases 0.000 title 1
- 210000002751 lymph Anatomy 0.000 abstract 4
- ZAHRKKWIAAJSAO-UHFFFAOYSA-N rapamycin Natural products COCC(O)C(=C/C(C)C(=O)CC(OC(=O)C1CCCCN1C(=O)C(=O)C2(O)OC(CC(OC)C(=CC=CC=CC(C)CC(C)C(=O)C)C)CCC2C)C(C)CC3CCC(O)C(C3)OC)C ZAHRKKWIAAJSAO-UHFFFAOYSA-N 0.000 abstract 3
- 229960002930 sirolimus Drugs 0.000 abstract 3
- 210000001519 tissue Anatomy 0.000 abstract 3
- 206010028980 Neoplasm Diseases 0.000 abstract 2
- 230000000694 effects Effects 0.000 abstract 2
- 239000003053 toxin Substances 0.000 abstract 2
- 231100000765 toxin Toxicity 0.000 abstract 2
- 108700012359 toxins Proteins 0.000 abstract 2
- 239000011248 coating agent Substances 0.000 abstract 1
- 238000000576 coating method Methods 0.000 abstract 1
- 239000003937 drug carrier Substances 0.000 abstract 1
- 230000001747 exhibiting effect Effects 0.000 abstract 1
- 230000003308 immunostimulating effect Effects 0.000 abstract 1
- 210000003734 kidney Anatomy 0.000 abstract 1
- 239000007788 liquid Substances 0.000 abstract 1
- 230000003211 malignant effect Effects 0.000 abstract 1
- 210000002307 prostate Anatomy 0.000 abstract 1
- 210000004872 soft tissue Anatomy 0.000 abstract 1
- 101150081449 stxA gene Proteins 0.000 abstract 1
- 210000001550 testis Anatomy 0.000 abstract 1
- 210000000626 ureter Anatomy 0.000 abstract 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61L—METHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
- A61L31/00—Materials for other surgical articles, e.g. stents, stent-grafts, shunts, surgical drapes, guide wires, materials for adhesion prevention, occluding devices, surgical gloves, tissue fixation devices
- A61L31/14—Materials characterised by their function or physical properties, e.g. injectable or lubricating compositions, shape-memory materials, surface modified materials
- A61L31/16—Biologically active materials, e.g. therapeutic substances
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61F—FILTERS IMPLANTABLE INTO BLOOD VESSELS; PROSTHESES; DEVICES PROVIDING PATENCY TO, OR PREVENTING COLLAPSING OF, TUBULAR STRUCTURES OF THE BODY, e.g. STENTS; ORTHOPAEDIC, NURSING OR CONTRACEPTIVE DEVICES; FOMENTATION; TREATMENT OR PROTECTION OF EYES OR EARS; BANDAGES, DRESSINGS OR ABSORBENT PADS; FIRST-AID KITS
- A61F2/00—Filters implantable into blood vessels; Prostheses, i.e. artificial substitutes or replacements for parts of the body; Appliances for connecting them with the body; Devices providing patency to, or preventing collapsing of, tubular structures of the body, e.g. stents
- A61F2/02—Prostheses implantable into the body
- A61F2/04—Hollow or tubular parts of organs, e.g. bladders, tracheae, bronchi or bile ducts
- A61F2/06—Blood vessels
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/47—Quinolines; Isoquinolines
- A61K31/4738—Quinolines; Isoquinolines ortho- or peri-condensed with heterocyclic ring systems
- A61K31/4745—Quinolines; Isoquinolines ortho- or peri-condensed with heterocyclic ring systems condensed with ring systems having nitrogen as a ring hetero atom, e.g. phenantrolines
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61L—METHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
- A61L31/00—Materials for other surgical articles, e.g. stents, stent-grafts, shunts, surgical drapes, guide wires, materials for adhesion prevention, occluding devices, surgical gloves, tissue fixation devices
- A61L31/08—Materials for coatings
- A61L31/10—Macromolecular materials
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61L—METHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
- A61L2300/00—Biologically active materials used in bandages, wound dressings, absorbent pads or medical devices
- A61L2300/40—Biologically active materials used in bandages, wound dressings, absorbent pads or medical devices characterised by a specific therapeutic activity or mode of action
- A61L2300/416—Anti-neoplastic or anti-proliferative or anti-restenosis or anti-angiogenic agents, e.g. paclitaxel, sirolimus
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61L—METHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
- A61L2420/00—Materials or methods for coatings medical devices
- A61L2420/08—Coatings comprising two or more layers
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Vascular Medicine (AREA)
- Epidemiology (AREA)
- Heart & Thoracic Surgery (AREA)
- Engineering & Computer Science (AREA)
- Surgery (AREA)
- Medicinal Chemistry (AREA)
- Chemical & Material Sciences (AREA)
- Biomedical Technology (AREA)
- Pulmonology (AREA)
- Transplantation (AREA)
- Oral & Maxillofacial Surgery (AREA)
- Cardiology (AREA)
- Gastroenterology & Hepatology (AREA)
- Molecular Biology (AREA)
- Pharmacology & Pharmacy (AREA)
- Medicinal Preparation (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Materials For Medical Uses (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Abstract
Με το δεσμευμένο αυτούσιο υπό νέα χρήση Cypher, (Cordis company), όπως και με τις καινοτόμες προσθήκες [ΝΕΕΣ] δυναμικών κατασκευαστικών μηχανικών μορφών φαρμακευτικών κλπ. καινούργιων, ή, υπό άλλο πρίσμα ιδωμένων παραμέτρων, (πχ SHIGA-Stx StxA toxinκλπ.) το όλο σύστημα, θα χρησιμοποιηθεί ανάλογα των εμπλεκομένων καταστάσεων, για παρεμπόδιση ανάπτυξης υπερπλαστικών ιστών, [λείων εν γένει] καλοήθους βάσης, η καρκινικών, λόγω των ιδιοτήτων της ραπαμυκίνης, να επιδρά ακριβώς εκεί, όπως και στα λεμφοκύτταρα [λεμφικός ιστός]. Ο νάρθηκας, δίκην σωληνωτού ελατηρίου, (stent) θα παρέξει εγνωσμένες μηχανικές ιδιότητες, εμπλουτισμένο δε με την τοξίνη, θα προκαλέσει περαιτέρω ανοσοδιέγερση. Δέσμευση επίσης και της προτεινόμενης απεικονιστικής δυνατότητας της ραπαμυκίνης για στοχευμένη αγκίστρωση και κακείθεν απεικόνιση του ογκικού δυναμικού-περιβάλλοντος αλλά και φαρμακευτική ομοίως δράση, [μεταφορέας φαρμάκων] σε λεμφικούς ιστούς εν γένει καθώς επίσης και της εννοιολογικής μεθοδολογικής επισήμανσης όλων των χρήσεων της, υπό οιανδήποτε μορφή [αυτούσιας, συνδεδεμένης, ως επίστρωση κλπ.] σε ουρολογικά πεδία, [αναφερόμενα στο κείμενο όπως νεφρό, προστάτης, όρχης, συναφείς λεμφαδένες, ουρητήρες. . . ], όπως και σε λεμφικούς ιστούς, εν γένει (υγρούς - συμπαγείς) χορηγούμενη σε υγρή μορφή από του στόματος, ή κατευθείαν στον όγκο, μόνη ή συνδεμένη, όπως στο κείμενο άπλετα αναφέρουμε. . . .
Priority Applications (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| GR20080100303A GR1006552B (el) | 2008-04-24 | 2008-04-24 | Ενδοπροστατικο ελατηριο-δοκιδα-βελονα/εγχυση/ενεσιμη μεθοδος |
| PCT/GR2009/000027 WO2009130518A1 (en) | 2008-04-24 | 2009-04-23 | Intraprostatic stent coil-bar-pin infusion /injection method |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| GR20080100303A GR1006552B (el) | 2008-04-24 | 2008-04-24 | Ενδοπροστατικο ελατηριο-δοκιδα-βελονα/εγχυση/ενεσιμη μεθοδος |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| GR1006552B true GR1006552B (el) | 2009-10-02 |
Family
ID=40791267
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| GR20080100303A GR1006552B (el) | 2008-04-24 | 2008-04-24 | Ενδοπροστατικο ελατηριο-δοκιδα-βελονα/εγχυση/ενεσιμη μεθοδος |
Country Status (2)
| Country | Link |
|---|---|
| GR (1) | GR1006552B (el) |
| WO (1) | WO2009130518A1 (el) |
Family Cites Families (5)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| IN2014DN10834A (el) * | 2001-09-17 | 2015-09-04 | Psivida Inc | |
| US20050255230A1 (en) * | 2004-05-17 | 2005-11-17 | Clerc Claude O | Method of manufacturing a covered stent |
| US20060067977A1 (en) * | 2004-09-28 | 2006-03-30 | Atrium Medical Corporation | Pre-dried drug delivery coating for use with a stent |
| CA2600711C (en) * | 2005-03-15 | 2014-07-08 | Surmodics, Inc. | Compliant polymeric coatings for insertable medical articles |
| US20070162110A1 (en) * | 2006-01-06 | 2007-07-12 | Vipul Bhupendra Dave | Bioabsorbable drug delivery devices |
-
2008
- 2008-04-24 GR GR20080100303A patent/GR1006552B/el active IP Right Grant
-
2009
- 2009-04-23 WO PCT/GR2009/000027 patent/WO2009130518A1/en not_active Ceased
Also Published As
| Publication number | Publication date |
|---|---|
| WO2009130518A1 (en) | 2009-10-29 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CA2819240C (en) | Aptamer bioconjugate drug delivery device | |
| CL2009001014A1 (es) | Composicion de insulina de accion superrapida que comprende insulina y una enzima de degradacion de hialuronano; sistema de lazo cerrado que comprende la composicion; metodo para preparar la composicion; uso de la composicion. | |
| WO2012018404A3 (en) | Use of her3 binding agents in prostate treatment | |
| MX341118B (es) | Cojugados de suministro de polinucleotidos in vivo que tienen acoplamientos sensibles a enzima. | |
| MX2016001006A (es) | Policonjugados para suministro de desencadenantes de acido ribonucleico de interferencia (arni) en celulas tumorales en vivo. | |
| MX2011003557A (es) | Vendas para heridas con capa de interfaz. | |
| ATE489048T1 (de) | Vorrichtung für kombinierte behandlung | |
| NZ591719A (en) | Balloon catheter medical device coated with therapeutic agent and povidone-iodine | |
| WO2013061083A3 (en) | Therapeutic agents and uses thereof | |
| WO2009127882A3 (en) | A mobile wireless device with an embedded media player | |
| HRP20180660T1 (hr) | Sustavi i postupci za liječenje tkiva prostate | |
| WO2009123824A3 (en) | Stent with nucleating agent | |
| CL2009000393A1 (es) | Composición farmaceutica que comprende a) un agente farmaceutico activable, b) un agente activo plasmonico; util para el tratamiento de trastornos de proliferación celular. | |
| EP4218718A3 (en) | Dermal delivery compositions comprising active agent-calcium phosphate particle complexes and methods of using the same | |
| EP2596425A4 (en) | Membership tracking and data eviction in mobile middleware scenarios | |
| WO2007128973A3 (en) | Interleukin 1-receptor antagonist composition to treat restenosis | |
| MX2012009490A (es) | Composicion en gel posespumante que comprende un agente contra la irritacion. | |
| DK2252322T3 (da) | Vaccinesammensætninger | |
| WO2011088178A3 (en) | Personal care composition comprising a hydrophobically modified cationic polysaccharide | |
| DK2124640T3 (da) | Glucoseisomerase til anvendelse i behandlingen af fruktoseintolerans | |
| WO2008090585A3 (en) | Soluble forms of inclusion complexes of histone deacetylase inhibitors and cyclodextrins, their preparation processes and uses in the pharmaceutical field | |
| GR1006552B (el) | Ενδοπροστατικο ελατηριο-δοκιδα-βελονα/εγχυση/ενεσιμη μεθοδος | |
| EP4233536A3 (en) | Method for enhancing tumor growth | |
| GEP20125689B (en) | New (poly)aminoalkylaminoalkylamide, alkyl-urea, or alkylsulfonamide derivatives of epipodophyllotoxin, preparation process thereof, and application thereat therapy as anticancer agents | |
| WO2014121224A3 (en) | Biodegradable iron oxide nanoparticle gel |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| PG | Patent granted |